Adam J N Raymakers (Adam Raymakers, A J N Raymakers)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 6

Top Topics

Palliative Care

Diffuse Large B Cell Lymphoma

Top Venues

Current oncology (Toronto, Ont.)

This page only lists publications with an associated author ORCID identifier.

Publications

Edward Robert Scheffer Cliff, Amar H Kelkar, David A Russler-Germain, Frazer A Tessema, Adam J N Raymakers, William B Feldman, Aaron S Kesselheim
High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 43 (2023)
Colene Bentley, Sara Izadi-Najafabadi, Adam J N Raymakers, Helen McTaggart-Cowan
Qualitative Research Informing a Preference Study on Selecting Cannabis for Cancer Survivor Symptom Management: Design of a Discrete Choice Experiment. The patient 15 (4) (2022)
Adam J N Raymakers, David Cameron, Scott Tyldesley, Dean A Regier
Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care. Current oncology (Toronto, Ont.) 28 (3) (2021)
Adam J N Raymakers, Kristina M Jenei, Dean A Regier, Michael M Burgess, Stuart J Peacock
Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review. PharmacoEconomics 39 (3) (2021)
Adam J N Raymakers, S Costa, D Cameron, D A Regier
Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin's lymphoma: a probabilistic analysis. BMC cancer 20 (1) (2020)
Adam J N Raymakers, Dean A Regier, Stuart J Peacock
Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review. Cancer 126 (1) (2019)